Innovation Pharmaceuticals Inc (IPIX)

[LilyGDog]

More FACTS! Thanks slcimmuno, B OM could be our first deal!

2018 = Nasdaq

Go Leo & IPIX!

OM - Magnitude of Unmet Need

Future OncologyVol. 13, No. 30 Special Report (December 2017)
US oncology-wide incidence, duration, costs and deaths from chemoradiation mucositis and antimucositis therapy benefits

Abstract only, full article behind paywall... reads as it'd be chock-full of OM data. Googled author, CEO of ProThelial... a Device for OM, so not playing in same ballpark as B-OM, other drugs in development... still some data on magnitude of OM need - costs, mortality -- again, liking our chances -- 60% or higher -- for BTD given FT given to every company going after OM and not nec showing prevention (like us, Galera -- two leaders, with our Oral Rinse the much better mode of delivery... and likely less expensive - per the bulk commercial-grade manufacturing legwork IPIX PR'd)

----

Approximate oncology-wide incidence, duration, costs and deaths associated with mucositis and identify health economic benefits of antimucositis therapies. Review the literature relevant to the clinical experience of mucositis by pathophysiology, incidence, duration, costs and deaths. Use US insurance actuarial and epidemiology on cancer to generalize an oncology-wide impact of toxic mucositis. Toxic mucositis causes oropharyngoesophageal ulcerations, chemo-induced nausea, vomiting and diarrhea. Acutely, it lasts 102 days/six cycles of chemotherapy, 60 days in human stem-cell transplantation patients and 70–84 days in head and neck cancer patients at annual costs of US$13.23 billion/522,166 treated patients (US$20,892/erosive-type mucositis patient, US$25,337/physiologic mucositis patient) and 46,699 deaths. Using antimucositis therapies prior to 2013 provided fractional benefits at high costs. By completely preventing and rapidly reversing mucositis, high-potency polymerized cross-linked sucralfate promises superior health economic benefits.

https://www.futuremedicine.com/doi/abs/10.2217/fon-2017-0418

https://www.accessdata.fda.gov/cdrh_docs/pdf12/K123904.pdf